Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Septerna Inc. 250 East Grand Avenue South San Francisco, California 1 650 338-3533 ...

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Novo Nordisk produces the GLP-1 weight loss agonists Wegovy, Ozempic, and other medications that contain semaglutide, which has been shown to lower blood sugar and support weight loss.

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...